Researchers from Utrecht University, The Netherlands, have developed a model that illustrates how HIV evades the immune system. The study, published July 18th in the open-access journal PLoS Computational Biology, incorporates detailed interactions between a mutating virus and the immune system.
HIV avoids recognition by the human immune response through the generation of viral variants called "escape mutants". This avoidance seems to thwart effective control of virus replication, causing HIV-infected patients to progress to AIDS. However, it remains difficult to fully understand the dynamics of immune escape, as data from infected patients is relatively sparse.
Knowing this, Drs. Christian Althaus and Rob De Boer performed computer simulations to help interpret longitudinal data derived from HIV-infected patients. They illustrate that the virus often evades the immune response very slowly, on a timescale of years. Depending on the diversity of the immune system, the virus will either be controlled effectively or accumulate detrimental mutations. The results suggest an alternative strategy of vaccine design could be to reduce the replicative capacity of the virus.
Citation: Althaus CL, De Boer RJ (2008) Dynamics of Immune Escape during HIV/SIV Infection. PLoS Comput Biol 4(7): e1000103. doi:10.1371/journal.pcbi.1000103
Source: Public Library of Science
Related stories:
Scientists identify genetic link that may neutralize HIV
Scientists from the Gladstone Institute of Virology and Immunology (GIVI) and the National Institutes of Allergy and Infectious Diseases (NIAID) have identified a gene that may influence the production of antibodies that neutralize HIV. This new information will likely spur a new approach for making an HIV vaccine that elicits neutralizing antibodies. Neutralizing antibodies, once produced in the host, can attack and checkmate an infecting virus. The research was reported in the September 5 issue of
Science.
First gene associated with dry macular degeneration found
In a study that underscores the important role that individual genetic profiles will play in the development of new therapies for disease, a multi-institutional research team – led by Kang Zhang, MD, PhD professor of ophthalmology and human genetics at Shiley Eye Center at the University of California, San Diego, School of Medicine – has made two important discoveries related to age-related macular degeneration (AMD), the leading cause of blindness in adults over the age of 60.
Victims of Britain's tainted blood scandal speak
(AP) -- Robert Mackie trembles with rage when he describes how he and his wife were kept in the dark about his HIV infection - and how doctors published his medical data in journals years before they gave him the devastating news.
Chemical liberated by leaky gut may allow HIV to infect the brain
In up to 20 percent of people infected with HIV, the virus manages to escape from the bloodstream and cross into the brain, resulting in HIV-associated dementia and other cognitive disorders. Now, scientists at the Albert Einstein College of Medicine of Yeshiva University have found strong evidence that a component of the cell walls of intestinal bacteria—a chemical present in high levels in the blood of HIV-infected people—helps HIV to penetrate the usually-impregnable blood brain barrier (BBB). The findings, published in the August issue of the
Journal of Virology, could lead to strategies for preventing HIV from entering the brain and causing serious complications.
Personalized immunotherapy to fight HIV/AIDS
For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre (MUHC), in collaboration with Dr. Rafick Sékaly from the Université de Montréal, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients. The team's findings were presented on August 5 at the XVII International AIDS Conference in Mexico City.
Early treatment is key to combating hepatitis C virus
Canadian researchers have shown that patients who receive early treatment for Hepatitis C virus (HCV) within the first months following an infection, develop a rapid poly-functional immune response against HCV similar to when infection is erradicted spontaneously, according to a new study published in the
Journal of Virology. Therefore, early treatment can restore immune response against HCV and help eliminate the virus rapidly. This new discovery of the mechanisms of viral eradication could contribute to the development of new treatments.
Novel method to create personalized immunotherapy treatments
Argos Therapeutics and Université de Montréal today announced the presentation of new information on Argos' process for developing dendritic cell-based immunotherapies for HIV. Results from the study demonstrate that loading monocyte-derived dendritic cells with combinations of HIV antigen RNA stimulates the expansion of HIV-specific T cells, which attack and kill HIV-infected cells.
Study shows why treatment isn't effective for HIV
University of Minnesota researchers have answered a key question as to why antiretroviral therapy isn't effective in restoring immunity in HIV-infected patients.